[go: up one dir, main page]

WO2007075980A2 - Comprimes de lansoprazole se desintegrant oralement - Google Patents

Comprimes de lansoprazole se desintegrant oralement Download PDF

Info

Publication number
WO2007075980A2
WO2007075980A2 PCT/US2006/048961 US2006048961W WO2007075980A2 WO 2007075980 A2 WO2007075980 A2 WO 2007075980A2 US 2006048961 W US2006048961 W US 2006048961W WO 2007075980 A2 WO2007075980 A2 WO 2007075980A2
Authority
WO
WIPO (PCT)
Prior art keywords
sub
tablet
orally disintegrating
tablets
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/048961
Other languages
English (en)
Other versions
WO2007075980A8 (fr
WO2007075980A3 (fr
Inventor
David Isaac Silver
Limor Ari-Pardo
Sivan Antler
Nava Shterman
Simona Di Capua
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Teva Pharmaceuticals USA Inc
Original Assignee
Teva Pharmaceutical Industries Ltd
Teva Pharmaceuticals USA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP05257891A external-priority patent/EP1813275A1/fr
Priority claimed from PCT/US2005/046296 external-priority patent/WO2007078271A2/fr
Priority claimed from US11/314,656 external-priority patent/US20070141151A1/en
Priority to EP06848925A priority Critical patent/EP1962844A2/fr
Application filed by Teva Pharmaceutical Industries Ltd, Teva Pharmaceuticals USA Inc filed Critical Teva Pharmaceutical Industries Ltd
Priority to JP2008547591A priority patent/JP2009524592A/ja
Priority to CA002633825A priority patent/CA2633825A1/fr
Publication of WO2007075980A2 publication Critical patent/WO2007075980A2/fr
Publication of WO2007075980A3 publication Critical patent/WO2007075980A3/fr
Priority to IL191923A priority patent/IL191923A0/en
Anticipated expiration legal-status Critical
Publication of WO2007075980A8 publication Critical patent/WO2007075980A8/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)

Definitions

  • the invention is directed to enteric coated drugs, such as Lansoprazole.
  • the invention is directed to an easily swallowed tablet that readily disintegrate in the mouth releasing enteric coated drug sub-tablets.
  • Lansoprazole a substituted Benzimidazole, is an inhibitor of gastric
  • Lansoprazole has been shown to be unstable under acidic conditions, and, thus, preferably has an enteric coating to prevent exposure of the drug to acidic conditions prior to absorption in the digestive system.
  • Enteric coated products are known.
  • U.S. Patent No. 6,706,285 discloses an enteric coated Lansoprazole, having a core and a film of an enteric coating agent on the surface thereof, where the core contains a complex of the Lansoprazole and an ion-exchange resin.
  • Many enteric coated products are formulated as a single monolithic unit, such as that disclosed in U.S. Patent No. 6,706,285, while others comprise multiple units, where the multiple-unit formulations are formulated to improve migration in the digestive track, and to minimize various absorption issues.
  • Patent 6,328,994 discloses an orally disintegrable Lansoprazole tablet which comprises fine enteric coated "granules," having an average particle diameter of 400 ⁇ m or less.
  • European Patent EP 0 723 437Bl discloses an oral pharmaceutical multiple unit tableted dosage form, comprising individually enteric coating layered units characterized in that the enteric coating layer has a particular thickness, and comprises a plasticizer an amount of 15 to 50 percent by weight of the enteric coating layer polymer.
  • the present invention is directed to orally disintegrating tablets, comprising enteric coated sub-tablets, which comprise a drug, and to methods of preparing such tablets and sub-tablets, where the sub-tablets preferably have an average particle diameter of more than 400 ⁇ m, and the enteric coat preferably comprises less than 15 percent plasticizer by weight of the enteric coating layer polymer.
  • the drug is one that is unstable under acidic conditions, more preferably, the drug is a Benzimidazole derivative, such as Lansoprazole, Pantoprazole, Rabeprazole, Omeprazole, and Esomeprazole. Most preferably, the drug is Lansoprazole.
  • orally disintegrating tablets of the invention dissolve rapidly in a patients mouth, releasing the enteric coated sub-tablets, which can be swallowed without water.
  • the sub-tablets are enteric coated, the sub-tablets pass through the stomach without exposure of the drug to acidic conditions, avoiding degradation of the drug prior to absorption in the patient's digestive tract.
  • the compression of the enteric coated sub-tablets into the orally disintegrating tablets of the invention does not significantly affect the acid resistance of the individually enteric coated sub-tablets.
  • the orally disintegrating tablets of the invention comprise more than one enteric coated sub-tablet, mixed with one or more tablet excipients.
  • the sub-tablets comprise an inner core, substantially free of any alkaline stabilizing agent, where each core comprises one or more inert core excipients and an acid sensitive drug in, on, or over the inner core; an inert first coating layer, disposed over the acid sensitive drug; an alkaline stabilizing layer, comprising an alkaline stabilizing agent, disposed over the inner core and the acid sensitive drug; and an enteric coating layer, which is preferably polymeric and plasticized with less than 15 percent plasticizer, disposed over the alkaline stabilizing layer, where the inert first coating layer is substantially free of and inert with regard to both the acid sensitive drug and the alkaline stabilizing layer.
  • the inert first coating layer substantially improves the stability of the acid sensitive drug.
  • the orally disintegrating tablets of the invention preferably comprise inner cores, having at least two sub-populations, each sub-population having a different size distribution.
  • the inner cores can be composed of a single population, having a single size distribution.
  • the orally disintegrating tablets of the invention disintegrate, facilitating swallowing of the orally disintegrating tablet by a patient.
  • the inner core can also be an extrusion, comprising the acid sensitive drug and one or more excipients.
  • the acid sensitive drug comprises a Benzimidazole derivative, such as Lansoprazole, Pantoprazole, Rabeprazole, Omeprazole, and Esomeprazole.
  • the drug comprises Lansoprazole.
  • the orally disintegrating tablets of the invention preferably comprise no more than about 50 percent by weight sub-tablets. Alternatively, the tablets may comprise about 35 % to about 50%, about 40% to about 50%, or about 40% to about 45%.
  • the acid sensitive drug can be in, on, or over the inner core, such that the sub-tablets of the orally disintegrating tablet can comprise a drug layer disposed over the inner core, where the drug layer comprises the acid sensitive drug, the inert first coating layer, disposed over the drug layer, and the alkaline stabilizing layer disposed over the inert first coating layer.
  • the drug layer, the inert first coating layer and the alkaline stabilizing layer can comprise at least one of a film forming agent and at least one excipient.
  • sub-tablets useful in the invention comprise an inner, inert core, such as sugar spheres, coated with an acid labile drug, preferably a Benzimidazole derivative, such as Lansoprazole, Pantoprazole, Rabeprazole, Omeprazole, and Esomeprazole, and, more preferably, Lansoprazole, an inert first coating layer, substantially free of the alkaline stabilizing agent and acid labile drug, a second coating layer, comprising an alkaline stabilizing agent, and an outer coating, comprising an enteric coating.
  • an acid labile drug preferably a Benzimidazole derivative, such as Lansoprazole, Pantoprazole, Rabeprazole, Omeprazole, and Esomeprazole
  • Lansoprazole an inert first coating layer, substantially free of the alkaline stabilizing agent and acid labile drug
  • a second coating layer comprising an alkaline stabilizing agent
  • an outer coating comprising
  • the materials of the inert core and the acid labile drug can be combined to form the sub-tablet core by, e.g., extruding a formulated particle composed of an acid labile drug and excipients, without departing from the scope of the invention.
  • An orally disintegrating tablet of the invention comprising such co-extruded cores, further comprises an inert first coating layer and an outer enteric coating.
  • Useful film forming agents include hypromellose, i.e., hydroxypropyl methylcellulose, and useful excipients include talc, more preferably, extra fine talc.
  • the ratio of the weight of the drug relative to the total weight of the film forming agent and excipient is preferably from about 1 :3 to about 3:1, more prerably about 1 :2 to about 2: 1 or about 1 :1.
  • the film forming agent and excipient can be used in any useful relative amount, and are preferably used in about equal amounts by weight.
  • the inert first coating layer comprises a film forming agent and an excipient. More preferably, the film forming agent is hypromellose and/or the excipient is talc, preferably, extra fine talc.
  • the weight ratio of film forming agent to excipient is preferably from about 1 :1 to about 1 :2, and, more preferably, is about 2:3.
  • the alkaline stabilizing agent of the alkaline stabilizing layer preferably comprises a carbonate, such as calcium or magnesium carbonate or a mixture thereof, and, more preferably, the alkaline stabilizing layer further comprises a film forming agent, such as hypromellose.
  • the weight ratio of the alkaline stabilizing agent to the film forming agent is preferably from about 1:1 to about 2:1, and, more preferably, is from about 1:1 to about 3:2.
  • the enteric coating is polymeric, and comprises at least one of hypromellose phthalate and methacrylic and methacrylate copolymers.
  • the methacrylic and methacrylate copolymers are preferably selected from the group consisting of a methacrylic acid copolymer type B, a methacrylic acid copolymer type C, a methacrylic acid, methylmethacrylate, and methylmethacrylate copolymer, a methacrylate copolymer, and mixtures thereof.
  • Such polymeric materials are available under the trade name EUDRAGIT ® .
  • the enteric coating can further comprises a plasticizer and/or excipients.
  • the plasticizer is less than 15 percent of the enteric coat polymer.
  • Useful plasticizer materials include, but are not limited to, triethyl citrate, and useful excipients include, but are not limited to talc, preferably, extra fine talc, and titanium dioxide.
  • the inner cores can be composed of a single population, having a single size distribution.
  • the orally disintegrating tablets preferably comprise at least first and second sub-populations of the inner cores, where the inner cores in the first sub-population have smaller diameters than the inner cores of the second population.
  • the weight ratio of the first and second sub-populations of inner cores is preferably from about 1:1 to about 4:1. More preferably, the weight ratio is from about 2:1 to about 3:1.
  • the acid sensitive drug is Lansoprazole
  • the first sub-population preferably has a size distribution of diameters of from about 250 to about 350 ⁇ m
  • the second sub-population has a size distribution of diameters of from about 400 to about 500 ⁇ m.
  • an orally disintegrating tablet comprises a single population of sub-tablets, having a single size distribution
  • the sized distribution is preferably within the range of from about 250 to about 500 ⁇ m.
  • the diameter of the sub-tablets becomes much greater than the diameter of the inner cores from which they are made, and, thus, a sub-population of inner cores with an average diameter of 300 ⁇ m will typically become, after coating, sub-tablets with an average diameter in excess of 400 ⁇ m, and a sub-population of inner cores with an average diameter of 450 ⁇ m will typically become, after coating, sub-tablets with an average diameter in excess of 600 ⁇ m.
  • the orally disintegrating tablet is a compressed tablet comprising the sub-tablets and tablet excipients, where at least one of the excipients preferably functions as a disintegrant.
  • the tablet excipients preferably comprise at least one of a starch or cellulose, a hydrated sugar, and silica, where, more preferably, the starch or cellulose is maize starch cellulose powder, the hydrated sugar is lactose monohydrate, and the silica is colloidal silica.
  • the orally disintegrating tablets can further comprise sweeteners and flavorings. Useful sweeteners include, but are not limited to, sugars, aspartame, and other commercially available artificial sweeteners.
  • the orally disintegrating tablets can further comprise a lubricant or plasticizer, such as magnesium stearate.
  • orally disintegrating tablets of the invention comprise a plurality of sub-tablets, mixed with one or more excipients, and formed into a tablet shape.
  • the sub-tablets comprise coated inner cores, coated with a coating comprising a drug; an inert first coating layer that is substantially free of any alkaline stabilizing agent and the drug, disposed over the inner core; an alkaline stabilizing layer, comprising an alkaline stabilizing agent, disposed over the inert first coating layer; and an outer enteric coating disposed over the alkaline stabilizing layer.
  • the inner core is formed from any useful material that will readily release the drug in the digestive system, is consumable by a patient, and does not degrade the drug.
  • the inner core is formed from particles or granules of a sugar, such as sucrose, which can be spherical or any other useful shape.
  • the drug is an acid sensitive drug, and, more preferably, is a Benzimidazole derivative, such as Lansoprazole, Pantoprazole, Rabeprazole, Omeprazole, and Esomeprazole. Most preferably, the drug is Lansoprazole.
  • the orally disintegrating tablets comprise a plurality of sub-tablets, mixed with one or more excipients, and formed into a tablet shape.
  • the sub-tablets comprise an inner core, comprising an acid sensitive drug and inert excipients, but free of any alkaline stabilizing agent; an inert first coating layer, substantially free of the drug and alkaline stabilizing agent; an alkaline stabilizing layer, comprising an alkaline stabilizing agent; and an outer coating layer, comprising an enteric coating.
  • the inner core is formed from any useful material that will readily release the drug in the digestive system, is consumable by a patient, and does not degrade the drug.
  • the inner core is formed from a sugar, such as sucrose.
  • the drug is a Benzimidazole derivative, such as Lansoprazole, Pantoprazole, Rabeprazole, Omeprazole, and Esomeprazole.
  • the drug is Lansoprazole.
  • the invention is further directed to a method of preparing orally disintegrating tablets.
  • the method comprises obtaining a plurality of inner cores, comprising an excipient and an acid sensitive drug, which is preferably a Benzimidazole derivative, such as Lansoprazole, Pantoprazole, Rabeprazole, Omeprazole, and Esomeprazole, in the core or in a layer over the core, applying an inert first coating layer, substantially free of the acid sensitive drug and alkaline stabilizing agent, over the acid sensitive drug and the inner cores, applying an alkaline stabilizing layer, comprising an alkaline stabilizing agent, over the inert first coating layer, applying an enteric coating layer, which is preferably polymeric, over the alkaline stabilizing layer, thereby forming enteric coated sub-tablets, and then mixing the enteric coated sub-tablets with one or more excipients, forming a tablet mixture, and compressing a portion of the resulting tablet mixture into an orally disintegrating tablet.
  • the method of preparing orally disintegrating tablets of the invention can further comprise applying a layer of the acid sensitive drug over the inner cores, and applying the inert first coating layer over the drug layer, prior to applying the alkaline stabilizing layer.
  • the amount of excipient in the tablet mixture is sufficiently great relative to the amount of enteric coated sub-tablets, and the enteric coating layer is sufficiently flexible, that cracking of the enteric coating during compression of the tablet is minimized, and upon exposure to a solution having a pH of about 3.5 for about 20 minutes, no more than about 10 percent by weight of the acid sensitive drug is dissolved by the solution.
  • at least one of the layers is applied by spraying.
  • orally disintegrating tablets in accordance with the invention can be prepared by providing inner cores, and preparing separate dispersions of the ingredients of the drug layer, the inert first coating layer, the alkaline stabilizing layer, and the enteric coating, where each dispersion is formed in a solvent.
  • the solvent is preferably purified water.
  • the solvent preferably comprises an organic solvent, and, more preferably, is a mixture of acetone and isopropyl alcohol. Most preferably, the isopropyl alcohol and acetone are used in a ratio of about 2:3.
  • the drug layer dispersion is applied over the inner cores, and preferably allowed to dry.
  • the dispersion of the inert first coating layer is applied over the drug layer, and preferably allowed to dry.
  • the dispersion of the alkaline stabilizing layer is applied over the inert first coating layer, and preferably allowed to dry, and the dispersion of the enteric coating is applied over the alkaline stabilizing layer, and preferably allowed to dry.
  • each layer is applied by spraying, and, more preferably, using a fluid bed drier.
  • the amount of solvent used in each dispersion is sufficient to allow the ready application of the dispersion, while minimizing the drying time.
  • the drug layer is deposited on the inner core, and allowed to dry
  • the inert first coating layer is deposited on the drug layer, and allowed to dry
  • the alkaline stabilizing layer is deposited on the inert first coating layer, and allowed to dry
  • the enteric coating is deposited on the alkaline stabilizing layer, and allowed to dry.
  • the each layer is deposited by spraying a dispersion of the material used to form the layer.
  • the final orally disintegrating tablets are preferably formed by mixing the enteric coated sub-tablets with the other tablet ingredients, and, preferably, pressing the mixture into tablets, comprising the desired dose of the drug.
  • the invention is further directed to a method of administering an acid sensitive drug, preferably a Benzimidazole derivative, such as, Lansoprazole, Pantoprazole, Rabeprazole, Omeprazole, and Esomeprazole, comprising orally administering at least one orally disintegrating tablet in accordance with the invention to a patient, where the orally disintegrating tablet at least partially disintegrates in the patients mouth, releasing the enteric coated sub-tablets, which are swallowed by the patient with or without the use of water or other fluid.
  • an acid sensitive drug preferably a Benzimidazole derivative, such as, Lansoprazole, Pantoprazole, Rabeprazole, Omeprazole, and Esomeprazole
  • Figure 1 illustrates a cross-section of an orally disintegrating tablet of the invention
  • Figure 2 illustrates a cross-section of one preferred embodiment of a sub-tablet of an orally disintegrating tablet
  • Figure 3 illustrates a cross-section of a further preferred embodiment of a sub-tablet.
  • the terms "on,” “disposed on,” and “deposited on” mean that a second material is disposed or deposited directly on, and in physical contact with a first material.
  • the terms “over,” disposed over,” and “deposited over”, as used herein, means that a second material is outside of a first material of the orally disintegrating tablets and sub-tablets of the invention, and can be, but need not be, in contact with the first material.
  • at least one intervening layer of material can be, but is not necessarily, disposed or deposited over the first material before the second materials is disposed or deposited.
  • the intervening layer of material can be disposed on or disposed over the first material.
  • inactive excipient refers to an excipient that does not reduce the effectiveness of the drug.
  • enteric refers to a material that is acid resistant, such that a sub-tablet coated with an enteric material resists dissolution in an acidic environment.
  • sub-tablet refers to any pellet, granule, powder, minitab, and the like having the sub-tablet structure described herein.
  • inert first coating layer of a sub-tablet refers to a coating layer that is inert with regard to any drug, core material, and alkaline stabilizing layer or agent in or on a sub-tablet, and is substantially free of any drug or alkaline stabilizing agent.
  • the present invention is directed to orally disintegrating tablets that are formulated to readily disintegrate in the mouth of a patient, thereby facilitating swallowing by a patient, preferably without requiring water.
  • the orally disintegrating tablets of the invention comprise at least one Benzimidazole derivative, such as Lansoprazole, Pantoprazole, Rabeprazole, Omeprazole, and Esomeprazole, but can be formulated for any drug that can be administered orally. Therefore, although the invention is described herein in terms of Lansoprazole orally disintegrating tablets (Lansoprazole ODT), orally disintegrating tablets, comprising other drugs, are within the scope of the invention.
  • Orally disintegrating tablets in accordance with the invention comprise a plurality of enteric coated sub-tablets containing at least one drug, such as Lansoprazole, mixed with an inactive blend of excipients, and formed into a single tablet, preferably by compression.
  • An orally disintegrating tablet 1 of the invention is illustrated in cross-section in Figure 1.
  • the orally disintegrating tablet 1 of the invention comprises a plurality of enteric coated sub-tablets 2, preferably dispersed within a mixture 3, comprising excipients, flavoring, and sweeteners, and formed into the tablet 1.
  • an enteric coated sub-tablet in an orally disintegrating tablet of the invention comprises:
  • An inner core such as, but not limited to, sugar particles or granules, which can be spherical or any other useful shape, coated with a drug, preferably, an acid sensitive drug, such as Lansoprazole, where the drug layer preferably comprises a film forming agent, such as hydroxypropyl methylcellulose (hypromellose) and an excipient, such as talc, preferably, extra fine talc, in addition to the drug;
  • a drug preferably, an acid sensitive drug, such as Lansoprazole
  • the drug layer preferably comprises a film forming agent, such as hydroxypropyl methylcellulose (hypromellose) and an excipient, such as talc, preferably, extra fine talc, in addition to the drug;
  • Subcoat I which is totally free of both any alkaline stabilizing agent and the drug, where the inert first coating layer preferably comprises a film forming agent, such as hypromellose, and an excipient, such as talc, preferably, extra fine talc;
  • Subcoat II that comprises an alkaline stabilizing agent, such as magnesium carbonate, and can further comprise a film forming agent, such as hypromellose; and
  • the tablet comprises, by weight of the tablet, about 5% to about
  • the tablet comprises, by weight of the tablet, about 0.5% to about
  • the first coating layer preferably comprises about 1% to about 20% of the total coated core, or about 2% to about 10%, or about 3% to about 6%.
  • the tablet comprises, by weight of the tablet, about 0.5% to about
  • the alkaline stabilizing layer preferably comprises about 1% to about 40% of the total coated core, or about 4% to about 20%, or about 6% to about 13%.
  • the tablet comprises, by weight of the tablet, about 5% to about
  • the outer coating preferably comprises about 10% to about 75% of the total coated core, or about 20% to about 60%, or about 25% to about 55%.
  • the tablet comprises, by weight of the tablet, about 30% to about
  • the tablet comprises, by weight of the tablet, about 1% to about
  • the acid sensitive drug comprises about 5% to about 20% of the total coated core, or about 8% to about ,15%, or about 8% to about 13%.
  • the tablet comprises, by weight of the tablet, about 0.5% to about
  • the alkaline stabilizing agent comprises about 1% to about 15% of the total coated core, or about 2% to about 10%, or about 3% to about 9%.
  • a sub-tablet 5 in accordance with this embodiment of the invention is illustrated in Figure 2.
  • the sub-tablet 5 comprises an inner core 6, a drug layer 7, an inert first coating layer 8, a alkaline stabilizing layer 9, and an enteric coating layer 10.
  • the inner core and the drug are combined into a single unit, produced, e.g., by extruding a formulated particle, comprising the drug, preferably, an acid sensitive drug, such as Lansoprazole, and excipients, without departing from the teachings of the invention.
  • the sub-tablet of the orally disintegrating tablet comprises: an inner core, comprising the acid sensitive drug and excipients, an inert first coating layer, substantially free of both the drug and any alkaline stabilizing agent, an alkaline stabilizing layer, comprising an alkaline stabilizing agent, and an outer coating agent, comprising an enteric coating.
  • a sub-tablet 15 in accordance with this embodiment of the invention is illustrated in Figure 3.
  • the sub-tablet 15 comprises a core 16, comprising at least one inactive excipient and the acid sensitive drug, an inert first coating layer 17, an alkaline stabilizing layer 18, and an enteric coating layer 19.
  • the inner cores are preferably sugar spheres, but can have any useful shape, and can comprise any useful material that will readily release the drug in the digestive system, is consumable by a patient, and does not degrade the drug. More preferably, the inner core is formed from a sugar, such as sucrose. Most preferably, the drug is a Benzimddazole derivative, such as Lansoprazole, Pantoprazole, Rabeprazole, Omeprazole, and Esomeprazole. In a preferred embodiment, the drug is Lansoprazole.
  • Parameters preferably considered during the formulation of orally disintegrating tablets of the invention include, but are not necessarily limited to the composition and size distribution of the inner cores, the material used for the enteric coating, which is preferably polymeric, and the excipients surrounding the inner cores.
  • the orally disintegrating tablets of the invention preferably comprise two or more populations, having different size distributions. The size distribution of each population and the relative amounts of the populations are preferably also considered during formulation of the orally disintegrating tablets.
  • the orally disintegrating tablets comprise a mixture of two sub-populations of inner cores, where the weight ratio of the core populations is preferably from about 1:1 to about 4:1, more preferably, from about 2:1 to about 3:1, where the weight ratio is the ratio of the total weight of the smaller cores to the total weight of the larger cores.
  • the weight ratio of the core populations is preferably from about 1:1 to about 4:1, more preferably, from about 2:1 to about 3:1, where the weight ratio is the ratio of the total weight of the smaller cores to the total weight of the larger cores.
  • one sub-population preferably has a range of diameters of from about 250 to about 350 ⁇ m
  • the second sub-population preferably has a range of diameters of from about 400 to about 500 ⁇ m.
  • Table 1 provides examples of different ratios of the various starting particle populations and different weights of cores per final tablet that have been prepared.
  • the total weight of inner cores per tablet varied between 50 nig to 120 mg. However, the final tablet weight was fairly similar, due to variation in the other ingredients.
  • the weight ratios of the two populations of cores in Table 1 were in the range of about 2:1 to about 3:1.
  • the total weight of inner cores per tablet and/or the amount of drug per sub-tablet can be adjusted to determine the dosage of tablets containing the sub-tablets.
  • the tablets exemplified in Table 1 were prepared as follows: An active compound dispersion consisting of Lansoprazole, hypromellose, extra fine talc and purified water was prepared by stirring. First and second sub-coat dispersions were prepared for forming the inert first coating layer and the alkaline stabilizing layer, the first sub-coat dispersion comprising hypromellose, extra fine talc, and purified water, and the second subcoat dispersion comprising hypromellose, magnesium carbonate, and purified water.
  • An outer enteric coating comprising a dispersion of EUDRAGIT ® L-100 55, titanium dioxide, extra fine talc, and triethyl citrate was prepared by stirring with acetone and isopropyl alcohol in a ratio of about 3:2. Sugar spheres were coated by consecutive spraying of the active dispersion subcoats (I + II) and the enteric coat layer using a fluid bed drier equipped with a W ⁇ rster column (bottom spray).
  • the polymers used for the enteric coating were also tested. As discussed above, Lansoprazole is unstable in an acidic environment.
  • the drug is provided with an enteric coating.
  • the dosage form is a tablet that comprises coated particles or granules, preferably in the form of spheres, mixed together with excipients.
  • the final tablets are preferably formed on a conventional tablet press without damage to the enteric coating layer of the coated particles during compression.
  • a flexible and/or malleable enteric coating layer was provided.
  • the tablet formulation preferably contains one or more types of polymer, alone or in a combination.
  • Example 10 exemplifies the use of EUDRAGIT ® L-100 55, a methacrylate copolymer, in a solvent, as an enteric coat
  • example 20 exemplifies a combination of two polymers, EUDRAGIT ® L-30 D-55, a methacrylic acid copolymer type C, and EUDRAGIT ® FS, a methacrylic acid, methylmethacrylate, and methylmethacrylate copolymer.
  • the enteric coat comprises hypromellose phthalate (HPMCP HP-55), and example 50 exemplifies a combination of two polymers, EUDRAGIT ® L- 100-55 and EUDRAGIT ® S-100, methacrylic acid copolymer type B.
  • the amount of plasticizer was not more than 10 percent by weight.
  • Dissolution tests were preformed using USP apparatus II at a pH of 3.5 for 20 minutes, at which time the pH of the dissolution medium was adjusted to 5.5 for a further 40 minutes.
  • the results of the dissolution tests are provided in Table 3.
  • the mean percentage drug dissolved after 20 minutes in the acid stage was significantly less than 10 percent by weight in each example.
  • compression during the formation of a final tablet can result in cleavage and crushing of the enteric layer.
  • dissolution at a pH of 5.5 was significantly greater than at pH 3.5.
  • example 10 appear to indicate that EUDRAGIT ® L-100 55 provides the most flexible and/or least damage prone enteric layer, as no drug was observed to dissolve at a pH of 3.5 after 20 minutes of exposure to those conditions. Since the formulation of example 60 is similar to that of example 10, the performance of example 60 should be the same as that of example 10.
  • the orally disintegrating tablets are intended to disintegrate rapidly in the mouth, and, thus, the selection of the types and amounts of excipients can be crucial to the disintegration of the Lansoprazole ODT in the mouth of a patient.
  • a tablet to disintegrate rapidly at least a portion of the excipients must function as a disintegrant.
  • the disintegrant enables the single tablet dosage form, comprising a compressed mixture of excipients and sub-tablets, to disintegrate, and release the sub-tablets.
  • Preferred excipients include, but are not limited to a spray-dried compound consisting of 85 percent by weight alpha-lactose monohydrate (Ph. Eur ./USP-NF) and 15 percent by weight maize starch (Ph. Eur./USP) dry matter, such as STARLACTM, from ROQUETTE, and a spray-dried compound comprising 75 percent by weight alpha-lactose monohydrate (Ph. Eur./USP-NF/JP) and 25 percent by weight cellulose powder (Ph. Eur.) dry matter, such as one CELLACTOSE ® 80, from MEGGLE. Examples of useful formulations are provided in Table 4.
  • the ratio of the weight of the coated spheres to that of the excipients in the tablet is very important.
  • Parameters that can affect the optimal ratio of the weight of the enteric coated pellets and that of the whole tablet include, but may not be limited to the uniformity of the content, hardness, friability and disintegration. Results of an evaluation of those parameters are provided in Table 5, where the Lansoprazole ODT were prepared with regard to the following specifications, an average content uniformity of from about 85 to about 115 percent by weight, a relative standard deviation (RSD) of not more than (NMT) 6 percent, a friability of not more than 2 percent, the time of disintegration, and the hardness.
  • RSD relative standard deviation
  • Formulation 200 which contains 40 percent by weight enteric coated pellets and STARLACTM.
  • Formulation 400 which contains 50 percent by weight enteric coated pellets and CELLACTOSE ® .
  • the formulations of the invention are sufficiently stable, such that, upon storage at 30 0 C and 65 percent relative humidity for 6 months, degradation products are typically formed through acid reaction of the acid sensitive drug in an amount of no more than 0.1 percent.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des comprimés qui se dissolvent facilement dans la bouche pour libérer le médicament contenu dans les comprimés entériques intérieurs enrobés.
PCT/US2006/048961 2005-12-20 2006-12-20 Comprimes de lansoprazole se desintegrant oralement Ceased WO2007075980A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002633825A CA2633825A1 (fr) 2005-12-20 2006-12-20 Comprimes de lansoprazole se desintegrant oralement
JP2008547591A JP2009524592A (ja) 2005-12-20 2006-12-20 ランソプラゾール経口崩壊錠剤
EP06848925A EP1962844A2 (fr) 2005-12-20 2006-12-20 Comprime oral desintegrable de lansoprazole
IL191923A IL191923A0 (en) 2005-12-20 2008-06-03 Lansoprazole orally disintegrating tablets

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
USPCT/US05/46296 2005-12-20
EP05257891.1 2005-12-20
EP05257891A EP1813275A1 (fr) 2005-12-20 2005-12-20 Comprime oral desintegrable de lansoprazole
US11/314,656 US20070141151A1 (en) 2005-12-20 2005-12-20 Lansoprazole orally disintegrating tablets
PCT/US2005/046296 WO2007078271A2 (fr) 2005-12-20 2005-12-20 Comprimes a desintegration orale de lansoprazole
US11/314,656 2005-12-20

Publications (3)

Publication Number Publication Date
WO2007075980A2 true WO2007075980A2 (fr) 2007-07-05
WO2007075980A3 WO2007075980A3 (fr) 2008-02-21
WO2007075980A8 WO2007075980A8 (fr) 2008-07-17

Family

ID=38218650

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/048961 Ceased WO2007075980A2 (fr) 2005-12-20 2006-12-20 Comprimes de lansoprazole se desintegrant oralement

Country Status (5)

Country Link
EP (1) EP1962844A2 (fr)
JP (1) JP2009524592A (fr)
CA (1) CA2633825A1 (fr)
IL (1) IL191923A0 (fr)
WO (1) WO2007075980A2 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009043926A3 (fr) * 2007-10-04 2009-10-15 Laboratorios Del Dr. Esteve, S.A. Comprimés oraux à désintégration rapide
WO2009113090A3 (fr) * 2008-01-17 2009-11-05 Alkem Laboratories Ltd. Procédé de préparation d’une formule orale d’un médicament à base de benzimidazole sensible à l’acide
CN101507718B (zh) * 2009-03-03 2011-05-04 张登科 雷贝拉唑钠肠溶口崩片及其制备方法
WO2011111027A3 (fr) * 2010-03-11 2012-03-01 Dexcel Pharma Technologies Ltd. Formulation de comprimé oral dispersible à libération retardée
US20120207843A1 (en) * 2009-08-12 2012-08-16 Debregeas Et Associes Pharma Floating microgranules
WO2012111024A1 (fr) * 2011-02-18 2012-08-23 Suven Nishtaa Pharma Pvt Ltd Compositions pharmaceutiques de dexlansoprazole
US9241910B2 (en) 2008-03-11 2016-01-26 Takeda Pharmaceutical Company Limited Orally-disintegrating solid preparation

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020055755A (ja) * 2018-09-28 2020-04-09 日本ケミファ株式会社 腸溶性製剤

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9402431D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New tablet formulation
ES2094694B1 (es) * 1995-02-01 1997-12-16 Esteve Quimica Sa Nueva formulacion farmaceuticamente estable de un compuesto de bencimidazol y su proceso de obtencion.
SK284291B6 (sk) * 1995-09-21 2005-01-03 Pharma Pass L.L.C. Farmaceutická kompozícia vo forme tabliet alebo mikrotabliet obsahujúca acidolabilný omeprazol a spôsob jej prípravy
SE9600070D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
AU3731699A (en) * 1998-05-18 1999-12-06 Takeda Chemical Industries Ltd. Orally disintegrable tablets
US20050214372A1 (en) * 2004-03-03 2005-09-29 Simona Di Capua Stable pharmaceutical composition comprising an acid labile drug

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009043926A3 (fr) * 2007-10-04 2009-10-15 Laboratorios Del Dr. Esteve, S.A. Comprimés oraux à désintégration rapide
WO2009113090A3 (fr) * 2008-01-17 2009-11-05 Alkem Laboratories Ltd. Procédé de préparation d’une formule orale d’un médicament à base de benzimidazole sensible à l’acide
US9241910B2 (en) 2008-03-11 2016-01-26 Takeda Pharmaceutical Company Limited Orally-disintegrating solid preparation
CN101507718B (zh) * 2009-03-03 2011-05-04 张登科 雷贝拉唑钠肠溶口崩片及其制备方法
US20120207843A1 (en) * 2009-08-12 2012-08-16 Debregeas Et Associes Pharma Floating microgranules
US8916202B2 (en) * 2009-08-12 2014-12-23 Debregeas Et Associes Pharma Floating microgranules
WO2011111027A3 (fr) * 2010-03-11 2012-03-01 Dexcel Pharma Technologies Ltd. Formulation de comprimé oral dispersible à libération retardée
WO2012111024A1 (fr) * 2011-02-18 2012-08-23 Suven Nishtaa Pharma Pvt Ltd Compositions pharmaceutiques de dexlansoprazole

Also Published As

Publication number Publication date
EP1962844A2 (fr) 2008-09-03
JP2009524592A (ja) 2009-07-02
WO2007075980A8 (fr) 2008-07-17
IL191923A0 (en) 2009-08-03
CA2633825A1 (fr) 2007-07-05
WO2007075980A3 (fr) 2008-02-21

Similar Documents

Publication Publication Date Title
US11452689B2 (en) Taste-masked pharmaceutical compositions
US10952971B2 (en) Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
EP1809251B1 (fr) Compositions pharmaceutiques multiparticulaires au gout masqué contenant les particules de noyaux et une membrane coacervée par les solvants
US20070141151A1 (en) Lansoprazole orally disintegrating tablets
WO2007078271A2 (fr) Comprimes a desintegration orale de lansoprazole
US20090202630A1 (en) Orally disintegrating tablet compositions of ranitidine and methods of manufacture
EP1813275A1 (fr) Comprime oral desintegrable de lansoprazole
WO2007075980A2 (fr) Comprimes de lansoprazole se desintegrant oralement
HK1104789A (en) Lansoprazole orally disintegrating tablets
HK1109337B (en) Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
HK1163502A (en) Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
HK1154515A (en) Taste-masked multiparticulate pharmaceutical composition comprising a drug-containing core particle and a solvent-coacervated membrane
HK1107272B (en) Taste-masked multiparticulate pharmaceutical compositions comprising a drug-containing core particle and a solvent-coacervated membrane

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2006848925

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2633825

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2008547591

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 5361/DELNP/2008

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06848925

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 200680053033.6

Country of ref document: CN